Table 1. Summary of study design.
Number of patients, doses of hyperpolarized [1-13C]pyruvate given, and types of MR examinations performed in each component of the study are provided.
| Study component | Dose (ml/kg) | n patients | Type of MR acquisition |
|---|---|---|---|
| Phase 1: Dose escalation | 0.14 | 3 | 1D dynamic MRSI |
| 3 | 3D MRSI | ||
| 0.28 | 3 | 1D dynamic MRSI | |
| 3 | 3D MRSI | ||
| 0.43 | 3 | 1D dynamic MRSI | |
| 3 | 2D MRSI | ||
| Phase 2: Refining MR methods | 0.43 | 5 | 2D dynamic MRSI |
| 3 | 2D MRSI | ||
| 5 | 3D MRSI |